-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $7

Benzinga·08/20/2026 15:49:32
Listen to the news
UBS analyst David Dai maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $4 to $7.